nach oben

Journal of Neural Transmission

Erschienen in:

31.12.2015 | Psychiatry and Preclinical Psychiatric Studies - Short communication

Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression

verfasst von: Bernd Kallmünzer, Bastian Volbers, Anne Karthaus, Ozan Yüksel Tektas, Johannes Kornhuber, Helge H. Müller

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

A lack of response despite maximum therapy is common in patients fulfilling criteria of treatment-resistant depression. Therefore, innovative strategies for treatment escalation are warranted. Here, we report the clinical experiences associated with a novel therapeutic regimen combining electroconvulsive therapy and repeated intravenous S-ketamine treatment in three patients. The combined therapy was feasible and had no serious side effects. All patients responded to the new treatment option. The augmentative effect of sub-anesthetic S-ketamine on ECT is discussed.

Abdallah CG, Averill LA et al (2015) Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 1344:66–77CrossRefPubMed

Bartova L, Vogl SE et al (2015) Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. Eur Neuropsychopharmacol 25:2183–2184CrossRefPubMed

Bromet E, Andrade LH et al (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9:90CrossRefPubMedPubMedCentral

Dang YH, Ma XC et al (2014) Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des 20:5151–5159CrossRefPubMed

Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500CrossRefPubMedPubMedCentral

Jarventausta K, Chrapek W et al (2013) Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 29(3):158–161CrossRefPubMed

Kornhuber J, Weller M (1995) Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. Convuls Ther 11(2):104–109PubMed

Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41(2):135–144CrossRefPubMed

Kubitz N, Mehra M et al (2013) Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One 8(10):e76882CrossRefPubMedPubMedCentral

Lecourtier L, Homayoun H et al (2007) Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 62(7):739–746CrossRefPubMedPubMedCentral

McGirr A, Berlim MT et al (2015) A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res 62:23–30CrossRefPubMed

Naughton M, Clarke G et al (2013) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156:24–35CrossRefPubMed

Pfleiderer B, Michael N et al (2003) Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 122(3):185–192CrossRefPubMed

Titel: Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression
verfasst von: Bernd Kallmünzer
Bastian Volbers
Anne Karthaus
Ozan Yüksel Tektas
Johannes Kornhuber
Helge H. Müller
Publikationsdatum: 31.12.2015
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 5/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-015-1500-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Reconstituting botulinum toxin drugs: shaking, stirring or what?

Botulinum toxin therapy: reduction of injection site pain by pH normalisation

Secondary task performance during challenging walking tasks and freezing episodes in Parkinson’s disease

Dysfunction in attentional processing in patients with Parkinson’s disease and visual hallucinations

Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI

Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie